...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population.
【24h】

Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population.

机译:过氧化物酶体增殖物激活受体-γ2(PPARgamma-2)基因的Pro12Ala多态性与更高的胰岛素敏感性和降低的伊朗人群中2型糖尿病的风险有关。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene has been variably associated with insulin resistance, obesity and type 2 diabetes in several populations. However, this association has not been studied in Iranian subjects and we hypothesized that this variation might be associated with insulin resistance, type 2 diabetes and related metabolic traits in this population. METHODS: The Pro12Ala genotypes were determined by PCR-restriction fragment length polymorphism in 696 unrelated subjects including 412 non-diabetic controls and 284 type 2 diabetic patients. RESULTS: The frequency of the Ala allele was 9.4% and 5.9% in controls and type 2 diabetic subjects, respectively [adjusted odds ratio (OR) 0.457, p=0.005]. The Ala allele did not show a significant effect on anthropometric and biochemical parameters in the type 2 diabetic group, whereas in non-diabetic subjects, carriers of the Ala allele had significantly lower fasting insulin (p=0.007) and homeostasis model assessment of insulin resistance (HOMA-IR) (p=0.009) levels compared to Pro/Pro subjects. Multivariate logistic regression analysis showed that Pro12Ala polymorphism was an independent determinant of type 2 diabetes in this population. CONCLUSIONS: Our results for a sample of Iranian type 2 diabetes cases and controls provide evidence that the Pro/Ala genotype of the PPARgamma-2 gene is associated with insulin sensitivity and may also have protective role against type 2 diabetes.
机译:背景:过氧化物酶体增殖物激活受体-γ2(PPARgamma-2)基因的Pro12Ala多态性已在多个人群中与胰岛素抵抗,肥胖症和2型糖尿病发生可变关系。但是,这种关联尚未在伊朗受试者中进行研究,我们假设这种变异可能与该人群中的胰岛素抵抗,2型糖尿病和相关的代谢特征有关。方法:通过PCR-限制性片段长度多态性测定了696例无关受试者中的Pro12Ala基因型,这些受试者包括412名非糖尿病对照和284名2型糖尿病患者。结果:对照组和2型糖尿病患者的Ala等位基因频率分别为9.4%和5.9%[校正比值比(OR)0.457,p = 0.005]。在2型糖尿病组中,Ala等位基因对人体测量和生化指标没有显着影响,而在非糖尿病受试者中,Ala等位基因的携带者的空腹胰岛素(p = 0.007)和胰岛素抵抗的稳态模型评估显着降低(HOMA-IR)(p = 0.009)水平与Pro / Pro受试者相比。多元逻辑回归分析表明,Pro12Ala多态性是该人群2型糖尿病的独立决定因素。结论:我们对伊朗2型糖尿病病例和对照样本的结果提供了证据,证明PPARgamma-2基因的Pro / Ala基因型与胰岛素敏感性相关,并且还可能对2型糖尿病具有保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号